Aminocaproic acid

Generic Name: Aminocaproic acid

Brand Names: Amicar

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₃NO_₂

CAS Number: 60-32-2

Unique Ingredient Identifier: U6F3787206

Background: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

Indication: For use in the treatment of excessive postoperative bleeding.

Associated Conditions: Hemorrhage

Clinical Trials

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Phase 4

Terminated

Conditions: Opioid Pain Medication

Interventions: Drug: Recombinant Human Thrombin
Drug: Lidocaine Hydrochloride with Epinephrine
Drug: Tranexamic acid
Drug: Aminocaproic acid
Drug: Bupivacaine Hydrochloride with Epinephrine

First Posted Date: 2021-03-24

Last Posted Date: 2024-06-26

Lead Sponsor: NYU Langone Health

Target Recruit Count: 46

Registration Number: NCT04814433

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Activated Factor Seven in Traumatic Retro Peritoneal Hematoma

Completed

Conditions: Traumatic Bleeding

Interventions: Device: ventilators
Drug: Novo Seven
Drug: aminocaproic acid

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-11

Lead Sponsor: King Abdul Aziz Specialist Hospital

Target Recruit Count: 80

Registration Number: NCT04424563

Locations: 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia

Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.

Phase 2

Completed

Conditions: Blood Loss
Blood Clot
Knee Osteoarthritis
Transfusion Related Complication

Interventions: Drug: Oral Tranexamic Acid
Drug: Oral Aminocaproic Acid

First Posted Date: 2017-12-08

Last Posted Date: 2019-07-30

Lead Sponsor: Universidad Autonoma de Nuevo Leon

Target Recruit Count: 92

Registration Number: NCT03365999

Locations: 🇲🇽
Facultad de Medicina UANL, Monterrey, Nuevo Leon, Mexico

A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery

Phase 4

Completed

Conditions: Pediatric Cardiac Surgery
Complication of Extracorporeal Circulation

Interventions: Drug: Tranexamic acid
Drug: Epsilon Aminocaproic Acid

First Posted Date: 2016-01-15

Last Posted Date: 2024-10-24

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 22

Registration Number: NCT02656472

Locations: 🇺🇸
Advocate Childrens Hospital, Oak Lawn, Illinois, United States

Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients

Phase 4

Conditions: Oral Hemorrhage

Interventions: Drug: Aminocaproic acid
Other: Routine dental care
Drug: lidocaine and epinephrine
Drug: Paracetamol

First Posted Date: 2014-09-12

Last Posted Date: 2014-09-12

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 154

Registration Number: NCT02238288

Locations: 🇧🇷
Clementino Fraga Filho University Hospital, Rio de Janeiro, RJ, Brazil

Efficacy of Amicar for Children Having Craniofacial Surgery

Phase 2

Active, not recruiting

Conditions: Craniosynostosis

Interventions: Drug: Amicar (ε-aminocaproic acid)
Drug: normal saline

First Posted Date: 2014-09-03

Last Posted Date: 2025-02-11

Lead Sponsor: Children's National Research Institute

Target Recruit Count: 22

Registration Number: NCT02229968

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Phase 2

Terminated

Conditions: Thrombocytopenia
Hematological Malignancies

Interventions: Other: Platelet transfusion
Drug: EACA

First Posted Date: 2014-02-28

Last Posted Date: 2022-07-19

Lead Sponsor: Emory University

Target Recruit Count: 29

Registration Number: NCT02074436

Locations: 🇺🇸
Atlanta VA Medical Center, Decatur, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

TXA vs. Amicar in Total Knee and Hip Arthroplasty

Phase 4

Completed

Conditions: Knee Arthritis
Blood Loss
Hip Arthritis

Interventions: Drug: TXA
Drug: Amicar

First Posted Date: 2014-01-09

Last Posted Date: 2018-12-05

Lead Sponsor: Duke University

Target Recruit Count: 246

Registration Number: NCT02030821

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty

Not Applicable

Conditions: Osteoarthritis

Interventions: Drug: Normal Saline
Drug: Epsilon Aminocaproic Acid
Drug: Tranexamic Acid

First Posted Date: 2012-02-07

Last Posted Date: 2016-07-26

Lead Sponsor: Heekin Orthopedic Research Institute

Target Recruit Count: 54

Registration Number: NCT01527968

Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery

Not Applicable

Completed

Conditions: Cardiopulmonary Bypass

Interventions: Drug: Tranexamic Acid
Drug: Aminocaproic Acid

First Posted Date: 2010-11-25

Last Posted Date: 2020-10-19

Lead Sponsor: Loma Linda University

Target Recruit Count: 100

Registration Number: NCT01248104

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy